Send PM
Followers 17
Posts 2022
Boards Moderated 1
Alias Born 10/23/2004

Re: AskMuncher post# 439

Monday, 08/30/2021 6:57:43 AM

Monday, August 30, 2021 6:57:43 AM

Post# of 453

by @accesswire on 30 Aug 2021, 12:31
Empower Clinics Reports 1,005% Year-Over-Year Revenue Growth in Q2 2021

The Company Increased Its Cash Position and Paid Off $2 Million in Debt

VANCOUVER, BC / ACCESSWIRE / August 30, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC PINK:EPWCF)(Frankfurt 8EC) (" Empower " or the " Company ") has filed today its consolidated financial statements and related management's discussion and analysis, both of which are available at All financial information in this press release is reported in United States dollars, unless otherwise indicated.

"Our second quarter was one of robust corporate development as we continue to execute our strategic growth vision while prioritizing the overall fiscal health of Empower Clinics," said Steven McAuley, Chairman and CEO. "By discontinuing certain operations in Q2, we paved the way for explosive growth across the company. We are excited about the R&D product development opportunities and increased testing available in Canada and the U.S. through the Kai Medical Laboratories expansion. We remain diligent on the progress of our Canadian clinic expansions and the distribution of MediSure devices. The entire Empower team is excited for the future."

Q2 2021 Highlights

Total revenues from continuing operations[1] of $861,826 for Q2 2021 compared to Q2 2020 revenues $85,775, representing 1005% year over year growth.
Cash at June 30, 2021 was $5,191,944 which increased from cash of $4,889,824 at December 31, 2020, primarily driven by the proceeds generated on exercise of share purchase warrants.
Cash used in operating activities of continuing operations was $416,949, compared to cash used of $171,848 for Q2 2020.
Loss from operations1 increased to $1,373,941 for Q2 2021 from $380,612 for Q2 2020, primarily driven by the increased corporate activity of the Company and legal and professional fees in pursuit of acquisitions.
Net loss from continuing operations1 of $412,209 or $0.00 per share compared to $501,419 or $0.00 per share for Q2 2020, which was primarily driven by a non-cash gain on the fair value adjustment related to the Company's warrants outstanding resulting from movement of the Company's share price (a key input in determining the fair value), offset by increased operating expenses.
Recent Highlights Subsequent to Quarter End

Sale of Sun Valley: In July 2021, the Company announced that it had entered into a non-binding agreement to sell its 100% ownership of Sun Valley to the previous owners of Sun Valley for total consideration of $1,000,000 payable in securities of Empower.
Acquisition : On July 30, 2021, the Company completed the acquisition of all ownership interest of Medi+Sure Canada Inc. for a total deemed purchase price of CAD$3.5M. Consideration consists of a cash payment of CAD$1,250,000 and 4,582,483 common shares of the Company, 2,036,659 of which are subject to contractual trading restrictions that will be removed quarterly over 24 months.
Common shares issued : The Company issued 21,176 shareswith a fair value of $0.41 (CAD$0.51) per share for proceeds of $9,023 (CAD$11,340) for marketing services and 125,000 shares from the exercise of stock options with an exercise price of $0.05 (C$0.06) for proceeds of $5,976 (CAD$7,500).
Financial Summary

US dollars, except where noted
Three months ended June 30,
2021 2020
Total revenues
861,826 85,775
Direct expenses
831,594 21,557
Loss from operations
1,373,941 380,612
Net loss from continuing operations
412,209 501,419
Net loss per share
- -
Financial Performance
Revenues for Q2 2021 and Q2 2020 were $861,826 and $85,775, respectively. This increase over prior year is attributable to the acquisition of Kai Medical and the strong revenue resulting from COVID-19 testing.

Direct expenses for Q2 2021 and Q2 2020 were $831,594 and $21,557, respectively. This increase over prior year is attributable to the acquisition of Kai which increased the Company's staffing levels and the ramp up of staffing as the Company expands its clinic presence in Canada through Lawrence Park & Atkinson.

Loss from operations for Q2 2021 and Q2 2020 were $1,373,941 and $380,612 respectively. This decrease from prior year is primarily attributable to the increase in revenues resulting from the acquisitions during fiscal 2020, offset by increased operating costs that are the direct result of consolidating the expenses of the acquired entities as well as the continued increase in corporate activity during Q2 2021 which increased legal and professional costs.

Net loss for Q2 2021 and Q2 2020 were $412,209 and $501,419, respectively. This decrease in loss over prior year is primarily attributable to the gain on change in fair value recognized on the warrant liability (as determined by the Black-Scholes option pricing model) which resulted from the decrease in the Company's share price between March 31, 2021 and June 30, 2021 and therefore the fair value allocated to warrants.

During Q2 2021, the Company used $416,949 in cash from continuing operations after changes in non-cash working capital. The Company invested $688,367 for the purchase of property and equipment and raised $258,336 via proceeds from various exercise of warrants and stock options, partially offset by lease payments and repayments of loans and notes payable in the amount of $104,483.

Please refer to the Company's condensed interim consolidated financial statements, related notes and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

Chief Executive Officer

Tamara Mason
Business Development & Communications

Steven McAuley